Sterility Testing Market

Sterility Testing Market by Product (Kits & Reagents, Instrument, Services), Test (Membrane Filtration, Direct Inoculation), Application (Pharma, Biological Manufacturing, Medical Device Manufacturing), End User (Pharma, Biotech) & Region - Global Forecasts to 2028

Report Code: BT 5095 Mar, 2023, by marketsandmarkets.com

The global sterility testing market in terms of revenue was estimated to be worth $1.1 billion in 2023 and is poised to reach $1.9 billion in 2028, growing at a CAGR of 10.5% from 2023 to 2028. The new research study consists of an industry trend analysis of the market. The new research study consists of industry trends, pricing analysis, patent analysis, conference and webinar materials, key stakeholders, and buying behaviour in the market.

Factors responsible for the growth in the market are mainly the rising expansion of pharmaceutical & biopharmaceutical production capacities, increasing development of novel biopharmaceutical products, and rising investments in life science research. However, the growing adoption of single-use technology is a major factor restraining the market growth.

Global Sterility Testing Market Trends

Sterility Testing Market

To know about the assumptions considered for the study, Request for Free Sample Report

Sterility Testing Market Dynamics

Driver: Rising expansion of pharmaceutical & biopharmaceutical production capacities

In pharmaceutical and biopharmaceutical industries, sterility testing is conducted at all manufacturing stages to minimize the risk of product contamination. Subsequently, the growth of this end-use industry in the coming years will considerably boost the utilization of sterility testing.

The production capacity expansion of pharmaceuticals and biopharmaceuticals worldwide will augment the demand for sterility testing products and services. Sterility testing is mandatory during the production process of pharmaceuticals and biopharmaceuticals. Therefore, the rising production capacities of pharmaceutical & biopharmaceutical companies will drive the adoption of additional kits, reagents, and instruments for sterility tests.

For instance:

  • In 2022, Novartis (Switzerland) invested USD 300 million to bolster the capacity and capabilities for next-generation bio-therapeutics across Switzerland, Slovenia, and Austria.
  • In 2022, Eli Lilly and Company (US) invested USD 1.5 billion to establish two new manufacturing facilities: Concord, NC, and Limerick, Ireland. Of the total investment, the company aims to invest USD 500 million, specifically in Limerick, to create a new biologics active ingredients site.

Restraint: Growing adoption of single-use technology

Single-use technology substitutes the stainless-steel and hard-piped configurations used in aseptic processing and sterile manufacturing. Gamma-irradiated pre-assembled process systems are used under single-use technology. Such technology is used for aseptic filling as well as upstream & downstream processing. The main benefit of SUT is that time and money are not invested in labor-intensive and expensive cleaning, sterilization validation tests, or their recurring revalidation. Moreover, it eliminates system cleaning and sterilization requirement between batches. Adopting such technologies will hamper the demand for sterility testing products and services.

However, the chances of human error will continue, even if closed systems and single-use technology are used more frequently. Personnel continues to be the principal source of contamination for pharmaceutical & biopharmaceutical formulations that cannot be terminally sterilized. Thus, a thorough training program is essential. When adhering to GMP and quality standards, operator comprehension is a crucial factor.

Opportunity: Emerging markets

Emerging markets such as Brazil, India, and China are expected to present significant opportunities for the growth of the market. This can mainly be attributed to increased R&D funding for research in these countries. For instance, China's current healthcare expenditure (% of GDP) went from 5.1% in 2017 to 5.4% in 2019. Similarly, for India, the healthcare expenditure rose from 2.9% in 2017 to 3.0% in 2019, while for Brazil, it was 9.5% in 2017 and increased to 9.6% in 2019. (Source: World Bank)

Moreover, CDMOs and CROs based in emerging markets offer cost-efficient development and manufacturing services to pharma & biotech companies. Sterility testing is a mandatory step in pharmaceutical drug discovery & development. Therefore, the growing production capacities of CROs and CDMOs in emerging nations will augment the demand for sterility testing products and services. A few examples of such capacity expansions are as follows:

  • In August 2022, Samsung Biologics announced plans to build a second biopharmaceutical campus, named Bio Campus II, at Songdo, Incheon, South Korea
  • In July 2022, Wuxi Biologics announced a USD 1.4 billion investment for expanding its research, development, and large-scale drug substance and drug product manufacturing capacity and capabilities in Singapore.

Challenge: Shortage of skilled professionals

The success of sterility tests depends mainly on the expertise of the analysts on the same par as the environmental conditions under which the test is performed. For optimal efficacy, sterility testing needs to be conducted by skilled professionals with sufficient knowledge of the nuances of this field. Handling the instruments used in sterility testing also requires expertise. Consequently, the shortage of a sufficiently skilled workforce poses a key challenge to the growth of the market.

In 2022, by product & service segment, the consumables segment accounted for the largest share of the sterility testing industry

Based on product, the sterility testing market is segmented into membrane filtration, direct inoculation, and other tests. In 2022, the kits & reagents segment accounted for the largest share of the global market. The large share of this segment can primarily be attributed to ease of use, recurring purchase, and growing preference associated with kits & reagents.

In 2022, by test type, the membrane filtration segment accounted for the largest share of the sterility testing industry

On the basis of type, the sterility testing market is segmented into membrane filtration, direct inoculation, and other tests. In 2022, the membrane filtration segment accounted for the largest share of the global market. Factors responsible for the large share of this segment are the growing demand for liquid formulations coupled with the suitability of such tests with samples containing preservatives and bacteriostatic & fungistatic compounds.

In 2022, North America accounted for the largest share of the sterility testing industry

In 2022, North America accounted for the largest share of the sterility testing market. Increasing drug approvals are expected to boost the market in the region. Additionally, the rising prevalence of diseases and the growing patient pool are increasing the demand and production for medicines in North America. The pharmaceutical & biotechnology industries in North America invest heavily in R&D and are expected to witness significant growth in the coming years, which in turn, is expected to drive the growth of the market.

Sterility Testing Market by Region

To know about the assumptions considered for the study, download the pdf brochure

The sterility testing market is dominated by a few globally established players such as Charles River Laboratories (US), Merck KGaA (Germany), bioMérieux SA (France), SGS SA (Switzerland), WuXi AppTec (China), Nelson Laboratories, LLC (US), Pacific BioLabs (US), Sartorius AG (Germany), Thermofisher Scientific Inc. (US), and Samsung Biologics (South Korea).

sterility testing Market Report Scope:

Report Metric

Details

Market Size Available for Years

2021–2028

Base Year Considered

2022

Forecast Period

2023–2028

Forecast Units

Value (USD Billion)

Segments Covered

Product & Service, Test Type, Application, End User, and Region

Geographies Covered

North America, Europe, Asia, and the Rest of the World

Companies Covered

The major market players include Charles River Laboratories (US), Merck KGaA (Germany), bioMérieux SA (France), SGS SA (Switzerland), WuXi AppTec (China), Nelson Laboratories, LLC (US), Pacific BioLabs (US), Sartorius AG (Germany), Thermofisher Scientific Inc. (US), Samsung Biologics (South Korea), GenScript (US), Pace Analytical (US), Rapid Micro Biosystems Inc (US), Tentamus Pharma (Germany). Singota Solutions (US), Neopharm Labs Inc. (Canada), LexaMed (US), Astell Scientifc (UK), HiMedia Laboratories (India), Pall Corporation (US), Boston Analytical (US), Solvias AG (Switzerland), and Becton, Dickinson, and Company (US).

The study categorizes the sterility testing market into the following segments & sub-segments:

By Product & Service

  • Kits & Reagents
  • Services
  • Instruments

By Test Type

  • Membrane Filtration
  • Direct Inoculation
  • Other Tests

By Application

  • Pharmaceuticals And Biologicals
  • Medical Devices
  • Other Applications

By End User

  • Pharmaceutical Companies
  • Biotechnology Companies
  • Others

By Region

  • North America
    • US
    • Canada
  • Europe
    • Germany
    • Italy
    • Spain
    • UK
    • France
    • Rest of Europe
  • Asia
    • China
    • Japan
    • India
    • South Korea
    • Rest of Asia
  • Rest of the World
    • Africa
    • Pacific and Oceania
    • South America, Central America, and the Caribbean

Recent Developments

  • In November 2022, Merck KGaA (Switzerland) invested USD 306.5 million in expanding its biosafety testing capacity at Rockville, Maryland, US. This site will provide biosafety testing and analytical development services in the US.
  • In September 2022, Merck KGaA (Switzerland) opened its viral clearance (VC) laboratory as the first phase of the China Biologics Testing Center. This site is set to operate in China and will locally conduct viral clearance studies across pre-clinical development to commercialization.
  • In June 2022, Charles River Laboratories, Inc. (US) opened a new facility of High Quality (HQ) Plasmid DNA Centre of Excellence at Bruntwood SciTech's Alderley Park in Cheshire, UK. The 16,000 sq. ft facility will provide plasmid DNA manufacturing services.
  • In May 2022, bioMérieux SA (France) acquired Specific Diagnostics (US). With this acquisition, bioMérieux will improve its presence in antimicrobial resistance while expanding its market-leading position globally in clinical microbiology.

Frequently Asked Questions (FAQ):

To speak to our analyst for a discussion on the above findings, click Speak to Analyst

TABLE OF CONTENTS
 
1 INTRODUCTION (Page No. - 27)
    1.1 STUDY OBJECTIVES 
    1.2 MARKET DEFINITION 
           1.2.1 INCLUSIONS AND EXCLUSIONS
    1.3 MARKET SCOPE 
           1.3.1 MARKETS COVERED
           1.3.2 YEARS CONSIDERED
    1.4 CURRENCY CONSIDERED 
    1.5 LIMITATIONS 
    1.6 STAKEHOLDERS 
    1.7 SUMMARY OF CHANGES 
           1.7.1 RECESSION IMPACT
 
2 RESEARCH METHODOLOGY (Page No. - 31)
    2.1 RESEARCH DATA 
          FIGURE 1 RESEARCH DESIGN
           2.1.1 SECONDARY RESEARCH
                    2.1.1.1 Secondary sources
           2.1.2 PRIMARY RESEARCH
                    2.1.2.1 Primary sources
                    2.1.2.2 Primary sources
                    2.1.2.3 Breakdown of primaries
                                FIGURE 2 MARKET: BREAKDOWN OF PRIMARIES
    2.2 MARKET SIZE ESTIMATION 
          FIGURE 3 MARKET SIZE ESTIMATION (2022)
          FIGURE 4 MARKET SIZE ESTIMATION METHODOLOGY: BOTTOM-UP APPROACH
          FIGURE 5 KEY INDUSTRY INSIGHTS
          FIGURE 6 MARKET: CAGR PROJECTION (2023–2028)
          FIGURE 7 MARKET: GROWTH ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
    2.3 MARKET BREAKDOWN AND DATA TRIANGULATION 
          FIGURE 8 DATA TRIANGULATION METHODOLOGY
    2.4 RESEARCH LIMITATIONS 
    2.5 RESEARCH ASSUMPTIONS 
    2.6 RISK ANALYSIS 
    2.7 RECESSION IMPACT 
           TABLE 1 GLOBAL INFLATION RATE PROJECTION, 2021–2027 (% GROWTH)
 
3 EXECUTIVE SUMMARY (Page No. - 44)
    FIGURE 9 STERILITY TESTING MARKET, BY PRODUCT & SERVICE, 2023 VS. 2028 (USD MILLION)
    FIGURE 10 MARKET, BY TEST TYPE, 2023 VS. 2028 (USD MILLION)
    FIGURE 11 MARKET, BY APPLICATION, 2023 VS. 2028 (USD MILLION)
    FIGURE 12 MARKET, BY END USER, 2023 VS. 2028 (USD MILLION)
    FIGURE 13 MARKET: GEOGRAPHICAL SNAPSHOT
 
4 PREMIUM INSIGHTS (Page No. - 48)
    4.1 STERILITY TESTING MARKET OVERVIEW 
          FIGURE 14 RISING EXPANSION OF PHARMACEUTICAL & BIOPHARMACEUTICAL PRODUCTION CAPACITIES TO FUEL UPTAKE OF STERILITY TESTING SERVICES
    4.2 ASIA: MARKET, BY PRODUCT & COUNTRY (2022) 
          FIGURE 15 KITS & REAGENTS SEGMENT ACCOUNTED FOR LARGEST MARKET SHARE IN CHINA
    4.3 MARKET, BY REGION (2022) 
          FIGURE 16 ASIA TO WITNESS HIGHEST GROWTH RATE DURING FORECAST PERIOD
 
5 MARKET OVERVIEW (Page No. - 51)
    5.1 INTRODUCTION 
    5.2 MARKET DYNAMICS 
          FIGURE 17 STERILITY TESTING MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, & CHALLENGES
           5.2.1 DRIVERS
                    5.2.1.1 Rising expansion of pharmaceutical & biopharmaceutical production capacities
                    5.2.1.2 Increasing development of novel biopharmaceutical products
                                TABLE 2 NOVEL DRUG APPROVALS (2022)
                    5.2.1.3 Rising investments in life sciences research
           5.2.2 RESTRAINTS
                    5.2.2.1 Growing adoption of single-use technology
                    5.2.2.2 Stringent regulatory guidelines for product approval
           5.2.3 OPPORTUNITIES
                    5.2.3.1 Emerging markets
                    5.2.3.2 Increasing outsourcing of services to sterility testing providers
           5.2.4 CHALLENGES
                    5.2.4.1 Shortage of skilled professionals
    5.3 TARIF AND REGULATION 
           5.3.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
                    TABLE 3 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
                    TABLE 4 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
                    TABLE 5 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
                    TABLE 6 REST OF THE WORLD: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
    5.4 PORTER’S FIVE FORCES ANALYSIS 
           TABLE 7 MARKET: PORTER’S FIVE FORCES ANALYSIS
           5.4.1 THREAT FROM NEW ENTRANTS
           5.4.2 THREAT FROM SUBSTITUTES
           5.4.3 BARGAINING POWER OF BUYERS
           5.4.4 BARGAINING POWER OF SUPPLIERS
           5.4.5 INTENSITY OF COMPETITIVE RIVALRY
    5.5 SUPPLY CHAIN ANALYSIS 
          FIGURE 18 MARKET: SUPPLY CHAIN ANALYSIS
    5.6 TECHNOLOGICAL ANALYSIS 
    5.7 INDICATIVE PRICING 
          TABLE 8 SELLING PRICE OF STERILITY TESTING PRODUCTS
    5.8 PATENT ANALYSIS 
          FIGURE 19 MARKET: PATENT TESTING APPLICATIONS (JANUARY 2012–DECEMBER 2022)
    5.9 ECOSYSTEM ANALYSIS 
          TABLE 9 MARKET: SUPPLY CHAIN ECOSYSTEM
    5.10 KEY CONFERENCES AND EVENTS, 2023–2024 
           TABLE 10 MARKET: CONFERENCES AND EVENTS (2023−2024)
    5.11 KEY STAKEHOLDERS AND BUYING CRITERIA 
           5.11.1 KEY STAKEHOLDERS IN BUYING PROCESS
                     FIGURE 20 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR STERILITY TESTING PRODUCTS
           5.11.2 MARKET: BUYING CRITERIA
                     FIGURE 21 KEY BUYING CRITERIA FOR END USERS
    5.12 TRADE ANALYSIS 
           TABLE 11 TOP 10 IMPORTERS OF MACHINERY AND APPARATUS FOR FILTERING/PURIFYING LIQUIDS (HS CODE – 842129)
           TABLE 12 TOP 10 EXPORTERS OF MACHINERY AND APPARATUS FOR FILTERING/PURIFYING LIQUIDS (HS CODE – 842129)
 
6 STERILITY TESTING MARKET, BY PRODUCT & SERVICE (Page No. - 68)
    6.1 INTRODUCTION 
          TABLE 13 MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)
    6.2 KITS & REAGENTS 
           6.2.1 RISING DEMAND FOR STANDARD STERILITY TESTING TO DRIVE MARKET
                    TABLE 14 MARKET FOR KITS & REAGENTS, BY REGION, 2021–2028 (USD MILLION)
                    TABLE 15 NORTH AMERICA: MARKET FOR KITS & REAGENTS, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 16 EUROPE: MARKET FOR KITS & REAGENTS, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 17 ASIA: MARKET FOR KITS & REAGENTS, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 18 REST OF THE WORLD: MARKET FOR KITS & REAGENTS, BY COUNTRY, 2021–2028 (USD MILLION)
    6.3 SERVICES 
           6.3.1 GROWING TREND OF OUTSOURCING SERVICES TO CROS TO DRIVE MARKET
                    TABLE 19 MARKET FOR SERVICES, BY REGION, 2021–2028 (USD MILLION)
                    TABLE 20 NORTH AMERICA: MARKET FOR SERVICES, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 21 EUROPE: MARKET FOR SERVICES, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 22 ASIA: MARKET FOR SERVICES, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 23 REST OF THE WORLD: MARKET FOR SERVICES, BY COUNTRY, 2021–2028 (USD MILLION)
    6.4 INSTRUMENTS 
           6.4.1 INCREASING ADOPTION OF RAPID MICROBIAL METHODS TO SUPPORT MARKET GROWTH
                    TABLE 24 MARKET FOR INSTRUMENTS, BY REGION, 2021–2028 (USD MILLION)
                    TABLE 25 NORTH AMERICA: MARKET FOR INSTRUMENTS, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 26 EUROPE: MARKET FOR INSTRUMENTS, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 27 ASIA: MARKET FOR INSTRUMENTS, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 28 REST OF THE WORLD: MARKET FOR INSTRUMENTS, BY COUNTRY, 2021–2028 (USD MILLION)
 
7 STERILITY TESTING MARKET, BY TEST TYPE (Page No. - 76)
    7.1 INTRODUCTION 
          TABLE 29 MARKET, BY TEST TYPE, 2021–2028 (USD MILLION)
    7.2 MEMBRANE FILTRATION 
           7.2.1 RISING DEMAND FOR TESTING OF DRUGS IN LIQUID DOSAGE FORMS TO FUEL ADOPTION
                    TABLE 30 MARKET FOR MEMBRANE FILTRATION, BY REGION, 2021–2028 (USD MILLION)
                    TABLE 31 NORTH AMERICA: MARKET FOR MEMBRANE FILTRATION, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 32 EUROPE: MARKET FOR MEMBRANE FILTRATION, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 33 ASIA: MARKET FOR MEMBRANE FILTRATION, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 34 REST OF THE WORLD: MARKET FOR MEMBRANE FILTRATION, BY COUNTRY, 2021–2028 (USD MILLION)
    7.3 DIRECT INOCULATION 
           7.3.1 ABILITY TO PROVIDE TESTING FOR MICROBIAL CONTAMINANTS TO DRIVE MARKET
                    TABLE 35 MARKET FOR DIRECT INOCULATION, BY REGION, 2021–2028 (USD MILLION)
                    TABLE 36 NORTH AMERICA: MARKET FOR DIRECT INOCULATION, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 37 EUROPE: MARKET FOR DIRECT INOCULATION, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 38 ASIA: MARKET FOR DIRECT INOCULATION, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 39 REST OF THE WORLD: MARKET FOR DIRECT INOCULATION, BY COUNTRY, 2021–2028 (USD MILLION)
    7.4 OTHER TEST TYPES 
          TABLE 40 MARKET FOR OTHER TEST TYPES, BY REGION, 2021–2028 (USD MILLION)
          TABLE 41 NORTH AMERICA: MARKET FOR KITS & REAGENTS, BY COUNTRY, 2021–2028 (USD MILLION)
          TABLE 42 EUROPE: MARKET FOR OTHER TEST TYPES, BY COUNTRY, 2021–2028 (USD MILLION)
          TABLE 43 ASIA: MARKET FOR OTHER TEST TYPES, BY COUNTRY, 2021–2028 (USD MILLION)
          TABLE 44 REST OF THE WORLD: MARKET FOR OTHER TEST TYPES, BY COUNTRY, 2021–2028 (USD MILLION)
 
8 STERILITY TESTING MARKET, BY APPLICATION (Page No. - 84)
    8.1 INTRODUCTION 
          TABLE 45 MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
    8.2 PHARMACEUTICAL & BIOLOGICS MANUFACTURING 
           8.2.1 GROWING PHARMACEUTICAL & BIOPHARMACEUTICAL PRODUCTION CAPACITIES TO DRIVE MARKET
                    TABLE 46 MARKET FOR PHARMACEUTICAL & BIOLOGICS MANUFACTURING, BY REGION, 2021–2028 (USD MILLION)
                    TABLE 47 NORTH AMERICA: MARKET FOR PHARMACEUTICAL & BIOLOGICS MANUFACTURING, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 48 EUROPE: MARKET FOR PHARMACEUTICAL & BIOLOGICS MANUFACTURING, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 49 ASIA: MARKET FOR PHARMACEUTICAL & BIOLOGICS MANUFACTURING, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 50 REST OF THE WORLD: MARKET FOR PHARMACEUTICAL & BIOLOGICS MANUFACTURING, BY COUNTRY, 2021–2028 (USD MILLION)
    8.3 MEDICAL DEVICE MANUFACTURING 
           8.3.1 RISING DEMAND FOR STERILITY TESTING OF MEDICAL DEVICES TO DRIVE MARKET
                    TABLE 51 MARKET FOR MEDICAL DEVICE MANUFACTURING, BY REGION, 2021–2028 (USD MILLION)
                    TABLE 52 NORTH AMERICA: MARKET FOR MEDICAL DEVICE MANUFACTURING, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 53 EUROPE: MARKET FOR MEDICAL DEVICE MANUFACTURING, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 54 ASIA: MARKET FOR MEDICAL DEVICE MANUFACTURING, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 55 REST OF THE WORLD: MARKET FOR MEDICAL DEVICE MANUFACTURING, BY COUNTRY, 2021–2028 (USD MILLION)
    8.4 OTHER APPLICATIONS 
          TABLE 56 MARKET FOR OTHER APPLICATIONS, BY REGION, 2021–2028 (USD MILLION)
          TABLE 57 NORTH AMERICA: MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2021–2028 (USD MILLION)
          TABLE 58 EUROPE: MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2021–2028 (USD MILLION)
          TABLE 59 ASIA: MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2021–2028 (USD MILLION)
          TABLE 60 REST OF THE WORLD: MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2021–2028 (USD MILLION)
 
9 STERILITY TESTING MARKET, BY END USER (Page No. - 93)
    9.1 INTRODUCTION 
          TABLE 61 MARKET, BY END USER, 2021–2028 (USD MILLION)
    9.2 PHARMACEUTICAL COMPANIES 
           9.2.1 GROWING EXPANSION OF PRODUCTION CAPACITIES AND STRONG PIPELINE OF NOVEL DRUGS TO DRIVE MARKET
                    TABLE 62 MARKET FOR PHARMACEUTICAL COMPANIES, BY REGION, 2021–2028 (USD MILLION)
                    TABLE 63 NORTH AMERICA: MARKET FOR PHARMACEUTICAL COMPANIES, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 64 EUROPE: MARKET FOR PHARMACEUTICAL COMPANIES, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 65 ASIA: MARKET FOR PHARMACEUTICAL COMPANIES, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 66 REST OF THE WORLD: MARKET FOR PHARMACEUTICAL COMPANIES, BY COUNTRY, 2021–2028 (USD MILLION)
    9.3 BIOTECHNOLOGY COMPANIES 
           9.3.1 RISING R&D INVESTMENTS IN BIOTECH FIRMS TO DRIVE MARKET
                    TABLE 67 MARKET FOR BIOTECHNOLOGY COMPANIES, BY REGION, 2021–2028 (USD MILLION)
                    TABLE 68 NORTH AMERICA: MARKET FOR BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 69 EUROPE: MARKET FOR BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 70 ASIA: MARKET FOR BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 71 REST OF THE WORLD: MARKET FOR BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2021–2028 (USD MILLION)
    9.4 OTHER END USERS 
          TABLE 72 MARKET FOR OTHER END USERS, BY REGION, 2021–2028 (USD MILLION)
          TABLE 73 NORTH AMERICA: MARKET FOR OTHER END USERS, BY COUNTRY, 2021–2028 (USD MILLION)
          TABLE 74 EUROPE: MARKET FOR OTHER END USERS, BY COUNTRY, 2021–2028 (USD MILLION)
          TABLE 75 ASIA: MARKET FOR OTHER END USERS, BY COUNTRY, 2021–2028 (USD MILLION)
          TABLE 76 REST OF THE WORLD: MARKET FOR OTHER END USERS, BY COUNTRY, 2021–2028 (USD MILLION)
 
10 STERILITY TESTING MARKET, BY REGION (Page No. - 101)
     10.1 INTRODUCTION 
             TABLE 77 MARKET, BY REGION, 2021–2028 (USD MILLION)
     10.2 NORTH AMERICA 
             FIGURE 22 NORTH AMERICA: STERILITY TESTING MARKET SNAPSHOT
             TABLE 78 NORTH AMERICA: MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
             TABLE 79 NORTH AMERICA: MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)
             TABLE 80 NORTH AMERICA: MARKET, BY TEST TYPE, 2021–2028 (USD MILLION)
             TABLE 81 NORTH AMERICA: MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
             TABLE 82 NORTH AMERICA: MARKET, BY END USER, 2021–2028 (USD MILLION)
             10.2.1 US
                        10.2.1.1 Rising growth in medical devices industry to fuel uptake
                                      TABLE 83 US: MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)
                                      TABLE 84 US: MARKET, BY TEST TYPE, 2021–2028 (USD MILLION)
                                      TABLE 85 US: MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
                                      TABLE 86 US: MARKET, BY END USER, 2021–2028 (USD MILLION)
             10.2.2 CANADA
                        10.2.2.1 Rising demand for pharmaceutical & biologics manufacturing to support market growth
                                      TABLE 87 CANADA: STERILITY TESTING MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)
                                      TABLE 88 CANADA: MARKET, BY TEST TYPE, 2021–2028 (USD MILLION)
                                      TABLE 89 CANADA: MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
                                      TABLE 90 CANADA: MARKET, BY END USER, 2021–2028 (USD MILLION)
             10.2.3 NORTH AMERICA: RECESSION IaMPACT
     10.3 EUROPE 
             TABLE 91 EUROPE: MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
             TABLE 92 EUROPE: MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)
             TABLE 93 EUROPE: MARKET, BY TEST TYPE, 2021–2028 (USD MILLION)
             TABLE 94 EUROPE: MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
             TABLE 95 EUROPE: MARKET, BY END USER, 2021–2028 (USD MILLION)
             10.3.1 GERMANY
                        10.3.1.1 Favorable R&D funding by federal & state governments to fuel uptake
                                      TABLE 96 GERMANY: STERILITY TESTING MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)
                                      TABLE 97 GERMANY: MARKET, BY TEST TYPE, 2021–2028 (USD MILLION)
                                      TABLE 98 GERMANY: MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
                                      TABLE 99 GERMANY: MARKET, BY END USER, 2021–2028 (USD MILLION)
             10.3.2 UK
                        10.3.2.1 Rising development of biotechnology manufacturing firms to drive market
                                      TABLE 100 UK: MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)
                                      TABLE 101 UK: MARKET, BY TEST TYPE, 2021–2028 (USD MILLION)
                                      TABLE 102 UK: MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
                                      TABLE 103 UK: MARKET, BY END USER, 2021–2028 (USD MILLION)
             10.3.3 FRANCE
                        10.3.3.1 Rising government initiatives for biologics manufacturing to support market growth
                                      TABLE 104 FRANCE: STERILITY TESTING MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)
                                      TABLE 105 FRANCE: MARKET, BY TEST TYPE, 2021–2028 (USD MILLION)
                                      TABaLE 106 FRANCE: MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
                                      TABLE 107 FRANCE: MARKET, BY END USER, 2021–2028 (USD MILLION)
             10.3.4 ITALY
                        10.3.4.1 Favorable government support for establishment of biotech startups to support market growth
                                      TABLE 108 ITALY: MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)
                                      TABLE 109 ITALY: MARKET, BY TEST TYPE, 2021–2028 (USD MILLION)
                                      TABLE 110 ITALY: MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
                                      TABLE 111 ITALY: MARKET, BY END USER, 2021–2028 (USD MILLION)
             10.3.5 SPAIN
                        10.3.5.1 Increasing focus on development of APIs to fuel uptake
                                      TABLE 112 SPAIN: STERILITY TESTING MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)
                                      TABLE 113 SPAIN: MARKET, BY TEST TYPE, 2021–2028 (USD MILLION)
                                      TABLE 114 SPAIN: MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
                                      TABLE 115 SPAIN: MARKET, BY END USER, 2021–2028 (USD MILLION)
             10.3.6 REST OF EUROPE
                        TABLE 116 REST OF EUROPE: MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)
                        TABLE 117 REST OF EUROPE: MARKET, BY TEST TYPE, 2021–2028 (USD MILLION)
                        TABLE 118 REST OF EUROPE: MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
                        TABLE 119 REST OF EUROPE: MARKET, BY END USER, 2021–2028 (USD MILLION)
             10.3.7 EUROPE: RECESSION IMPACT
     10.4 ASIA 
             FIGURE 23 ASIA: STERILITY TESTING MARKET SNAPSHOT
             TABLE 120 ASIA: MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
             TABLE 121 ASIA: MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)
             TABLE 122 ASIA: MARKET, BY TEST TYPE, 2021–2028 (USD MILLION)
             TABLE 123 ASIA: MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
             TABLE 124 ASIA: MARKET, BY END USER, 2021–2028 (USD MILLION)
             10.4.1 CHINA
                        10.4.1.1 Favorable government policies to increase drug manufacturing to drive market
                                      TABLE 125 CHINA: MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)
                                      TABLE 126 CHINA: MARKET, BY TEST TYPE, 2021–2028 (USD MILLION)
                                      TABLE 127 CHINA: MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
                                      TABLE 128 CHINA: MARKET, BY END USER, 2021–2028 (USD MILLION)
             10.4.2 JAPAN
                        10.4.2.1 Rising investments for cell & gene therapy facilities to support market growth
                                      TABLE 129 JAPAN: STERILITY TESTING MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)
                                      TABLE 130 JAPAN: MARKET, BY TEST TYPE, 2021–2028 (USD MILLION)
                                      TABLE 131 JAPAN: MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
                                      TABLE 132 JAPAN: MARKET, BY END USER, 2021–2028 (USD MILLION)
             10.4.3 INDIA
                        10.4.3.1 Increasing demand for biosimilars to drive market
                                      TABLE 133 INDIA: MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)
                                      TABLE 134 INDIA: MARKET, BY TEST TYPE, 2021–2028 (USD MILLION)
                                      TABLE 135 INDIA: MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
                                      TABLE 136 INDIA: MARKET, BY END USER, 2021–2028 (USD MILLION)
             10.4.4 SOUTH KOREA
                        10.4.4.1 Significant exports of pharmaceutical drugs to fuel uptake of sterility testing services
                                      TABLE 137 SOUTH KOREA: STERILITY TESTING MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)
                                      TABLE 138 SOUTH KOREA: MARKET, BY TEST TYPE, 2021–2028 (USD MILLION)
                                      TABLE 139 SOUTH KOREA: MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
                                      TABLE 140 SOUTH KOREA: MARKET, BY END USER, 2021–2028 (USD MILLION)
             10.4.5 REST OF ASIA
                        TABLE 141 REST OF ASIA: MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)
                        TABLE 142 REST OF ASIA: MARKET, BY TEST TYPE, 2021–2028 (USD MILLION)
                        TABLE 143 REST OF ASIA: MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
                        TABLE 144 REST OF ASIA: MARKET, BY END USER, 2021–2028 (USD MILLION)
     10.5 REST OF THE WORLD 
             TABLE 145 REST OF THE WORLD: STERILITY TESTING MARKET, BY REGION, 2021–2028 (USD MILLION)
             TABLE 146 REST OF THE WORLD: MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)
             TABLE 147 REST OF THE WORLD: MARKET, BY TEST TYPE, 2021–2028 (USD MILLION)
             TABLE 148 REST OF THE WORLD: MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
             TABLE 149 REST OF THE WORLD: MARKET, BY END USER, 2021–2028 (USD MILLION)
             10.5.1 SOUTH & CENTRAL AMERICA AND THE CARIBBEAN
                        10.5.1.1 Growing vaccine production to propel demand for sterility testing
                                      TABLE 150 SOUTH & CENTRAL AMERICA AND THE CARIBBEAN: MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)
                                      TABLE 151 SOUTH & CENTRAL AMERICA AND THE CARIBBEAN: MARKET, BY TEST TYPE, 2021–2028 (USD MILLION)
                                      TABLE 152 SOUTH & CENTRAL AMERICA AND THE CARIBBEAN: MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
                                      TABLE 153 SOUTH & CENTRAL AMERICA AND THE CARIBBEAN: MARKET, BY END USER, 2021–2028 (USD MILLION)
             10.5.2 PACIFIC AND OCEANIA
                        10.5.2.1 Improving investments in pharmaceutical R&D to fuel uptake
                                      TABLE 154 PACIFIC AND OCEANIA: STERILITY TESTING MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)
                                      TABLE 155 PACIFIC AND OCEANIA: MARKET, BY TEST TYPE, 2021–2028 (USD MILLION)
                                      TABLE 156 PACIFIC AND OCEANIA: MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
                                      TABLE 157 PACIFIC AND OCEANIA: MARKET, BY END USER, 2021–2028 (USD MILLION)
             10.5.3 AFRICA
                        10.5.3.1 Favorable government support for healthcare infrastructure to drive market
                                      TABLE 158 AFRICA: MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION)
                                      TABLE 159 AFRICA: MARKET, BY TEST TYPE, 2021–2028 (USD MILLION)
                                      TABLE 160 AFRICA: MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
                                      TABLE 161 AFRICA: MARKET, BY END USER, 2021–2028 (USD MILLION)
 
11 COMPETITIVE LANDSCAPE (Page No. - 144)
     11.1 OVERVIEW 
     11.2 STRATEGIES ADOPTED BY KEY PLAYERS 
             TABLE 162 STERILITY TESTING MARKET: KEY PLAYER STRATEGIES
     11.3 MARKET SHARE ANALYSIS 
             FIGURE 24 MARKET: MARKET SHARE ANALYSIS OF KEY PLAYERS IN 2022 (LEADING FOUR COMPANIES)
             TABLE 163 MARKET: INTENSITY OF COMPETITIVE RIVALRY
     11.4 REVENUE SHARE ANALYSIS OF KEY PLAYERS 
             FIGURE 25 MARKET: REVENUE SHARE ANALYSIS OF KEY PLAYERS (TOP FOUR)
     11.5 COMPANY EVALUATION QUADRANT 
             FIGURE 26 MARKET: COMPANY EVALUATION MATRIX (2022)
             11.5.1 STARS
             11.5.2 EMERGING LEADERS
             11.5.3 PERVASIVE PLAYERS
             11.5.4 PARTICIPANTS
     11.6 COMPANY EVALUATION QUADRANT: STARTUPS/SMES 
             FIGURE 27 MARKET: COMPANY EVALUATION MATRIX FOR STARTUPS/SMES (2022)
             11.6.1 PROGRESSIVE COMPANIES
             11.6.2 STARTING BLOCKS
             11.6.3 RESPONSIVE COMPANIES
             11.6.4 DYNAMIC COMPANIES
     11.7 COMPETITIVE BENCHMARKING 
             11.7.1 COMPANY PRODUCT FOOTPRINT
                        TABLE 164 MARKET: PRODUCT PORTFOLIO ANALYSIS
             11.7.2 COMPANY GEOGRAPHIC FOOTPRINT
                        TABLE 165 MARKET: GEOGRAPHIC ANALYSIS
     11.8 COMPETITIVE SCENARIO 
             TABLE 166 MARKET: DEALS (JANUARY 2019−JANUARY 2023)
             TABLE 167 MARKET: OTHER DEVELOPMENTS (JANUARY 2019−JANUARY 2023)
 
12 COMPANY PROFILES (Page No. - 156)
     12.1 KEY PLAYERS 
(Business Overview, Products/Services Offered, Recent Developments, and MnM View)*
             12.1.1 MERCK KGAA
                        TABLE 168 MERCK KGAA: BUSINESS OVERVIEW
                        FIGURE 28 MERCK KGAA: COMPANY SNAPSHOT (2021)
             12.1.2 CHARLES RIVER LABORATORIES
                        TABLE 169 CHARLES RIVER LABORATORIES: BUSINESS OVERVIEW
                        FIGURE 29 CHARLES RIVER LABORATORIES: COMPANY SNAPSHOT (2021)
             12.1.3 BIOMÉRIEUX SA
                        TABLE 170 BIOMÉRIEUX SA: BUSINESS OVERVIEW
                        FIGURE 30 BIOMÉRIEUX SA: COMPANY SNAPSHOT (2021)
             12.1.4 SGS S.A.
                        TABLE 171 SGS SA: BUSINESS OVERVIEW
                        FIGURE 31 SGS S.A.: COMPANY SNAPSHOT (2021)
             12.1.5 SARTORIUS AG
                        TABLE 172 SARTORIUS AG: BUSINESS OVERVIEW
                        FIGURE 32 SARTORIUS AG: COMPANY SNAPSHOT (2022)
             12.1.6 THERMO FISHER SCIENTIFIC INC.
                        TABLE 173 THERMO FISHER SCIENTIFIC: BUSINESS OVERVIEW
                        FIGURE 33 THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT (2022)
             12.1.7 WUXI APPTEC
                        TABLE 174 WUXI APPTEC: BUSINESS OVERVIEW
             12.1.8 SAMSUNG BIOLOGICS
                        TABLE 175 SAMSUNG BIOLOGICS: BUSINESS OVERVIEW
                        FIGURE 34 SAMSUNG BIOLOGICS: COMPANY SNAPSHOT (2021)
             12.1.9 GENSCRIPT
                        TABLE 176 GENSCRIPT: BUSINESS OVERVIEW
                        FIGURE 35 GENSCRIPT: COMPANY SNAPSHOT (2021)
             12.1.10 PACIFIC BIOLABS
                        TABLE 177 PACIFIC BIOLABS: BUSINESS OVERVIEW
             12.1.11 NELSON LABORATORIES, LLC
                        TABLE 178 NELSON LABORATORIES, LLC: BUSINESS OVERVIEW
* Business Overview, Products/Services Offered, Recent Developments, and MnM View might not be captured in case of unlisted companies.
     12.2 OTHER PLAYERS 
             12.2.1 PACE ANALYTICAL
             12.2.2 RAPID MICRO BIOSYSTEMS, INC.
             12.2.3 TENTAMUS
             12.2.4 SINGOTA SOLUTIONS
             12.2.5 NEOPHARM LABS INC.
             12.2.6 LEXAMED
             12.2.7 ASTELL SCIENTIFIC LTD
             12.2.8 HIMEDIA LABORATORIES
             12.2.9 PALL CORPORATION (PART OF DANAHER CORPORATION)
             12.2.10 BOSTON ANALYTICAL
             12.2.11 SOLVIAS AG
             12.2.12 BD
 
13 APPENDIX (Page No. - 192)
     13.1 DISCUSSION GUIDE 
     13.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 
     13.3 CUSTOMIZATION OPTIONS 
     13.4 RELATED REPORTS 
     13.5 AUTHOR DETAILS 

This research study involved extensive secondary sources, directories, and databases such as Hoovers, Bloomberg Business, and Factiva to identify and collect information useful for this technical, market-oriented, and commercial study of the sterility testing market. Primary sources included several industry experts from core and related industries and preferred suppliers, manufacturers, distributors, service providers, reimbursement providers, technology developers, alliances, and standards and certification organizations from companies and organizations related to all segments of this industry’s value chain. In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, to obtain and verify critical qualitative and quantitative information and assess prospects.

Secondary Research

The secondary sources referred to for this research study include publications from organizations such as the World Bank, World Health Organization (WHO), Centers for Disease Control and Prevention (CDC), National Cancer Institute (NCI), Food and Drug Administration (FDA), European Medicines Agency (EMA), National Comprehensive Cancer Network (NCCN), and National Institutes of Health (NIH). Secondary sources include corporate and regulatory filings (such as annual reports, SEC filings, investor presentations, and financial statements); business magazines and research journals; press releases; and trade, business, and professional associations. Secondary data was collected and analyzed to arrive at the overall size of the global Sterility testing market, which was validated through primary research.

Primary Research

In the primary research process, various supply and demand sources were interviewed to obtain qualitative and quantitative information for this report. Primary sources from the supply side include industry experts such as CEOs, vice presidents, marketing and sales directors, technology and innovation directors, and related key executives from various companies and organizations operating in the Sterility testing market. Primary sources from the demand side include industry experts such as software application specialists, product managers, medical device manufacturers, pharmaceutical firm R&D heads, packaging department heads, research scientists, and other related key opinion leaders. Primary research was conducted to validate the market segmentation, identify key players, and gather insights into key industry trends and market dynamics.

Breakdown of Primary Participants

Sterility Testing Market Size, and Share

To know about the assumptions considered for the study, download the pdf brochure

Market size Estimation

Segmental revenues were arrived at to calculate the global market value based on the revenue mapping of major players active in the Sterility testing market. This process involved the following steps:

  • Generating a list of the major global players operating in the sterility testing market
  • Mapping the annual revenues generated by major global players from the Sterility testing market or the nearest reported business unit/product category
  • Identifying the revenues of the top five players in the sterility testing market
  • Estimating the revenue of the key four players at 500-550 million in 2022 and adding up to 100% to derive the global value of the Sterility testing market

Data Triangulation

After arriving at the overall size of the sterility testing market through the methodology mentioned above, this market was split into several segments. Market breakdown procedures were employed, wherever applicable, to arrive at the exact market value for the key segments. The extrapolated market data was triangulated by studying various macro indicators and regional trends from both demand and supply-side participants.

Report Objectives

  • To define, describe, and forecast the sterility testing market based on product & service, test type, application, end-user, and region.
  • To provide detailed information regarding the major factors influencing the growth of the market (such as drivers, restraints, opportunities, and industry-specific challenges)
  • To strategically analyze micro markets concerning individual growth trends, future prospects, and contributions to the overall sterility testing market
  • To analyze the opportunities in the market for stakeholders and provide details of a competitive landscape for market leaders.
  • To profile key players and comprehensively analyze their market shares and core competencies regarding market development and growth strategies.
  • To forecast revenue of the market segments concerning four main regional segments, namely, North America, Europe, Asia, and the Rest of the World
  • To track and analyze competitive developments such as collaborations, mergers and acquisitions, product launches, and expansions in the sterility testing market.

Available Customizations:

With the given market data, MarketsandMarkets offers customizations as per the company’s specific needs. The following customization options are available for the report:

Geographic Analysis

  • Further breakdown of the European sterility testing market into RoE countries
  • Further breakdown of the Asia sterility testing market into RoA countries

Company Information

  • Detailed analysis and profiling of additional market players (up to 5)
Custom Market Research Services

We will customize the research for you, in case the report listed above does not meet with your exact requirements. Our custom research will comprehensively cover the business information you require to help you arrive at strategic and profitable business decisions.

Request Customization

Instant Answers with GPT - Ask Now!

Ask real questions. Get complete answers !
Report Code
BT 5095
Published ON
Mar, 2023
Choose License Type
BUY NOW
  • SHARE
X
Request Customization
Speak to Analyst
Speak to Analyst
OR FACE-TO-FACE MEETING
PERSONALIZE THIS RESEARCH
  • Triangulate with your Own Data
  • Get Data as per your Format and Definition
  • Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
  • Any level of Personalization
REQUEST A FREE CUSTOMIZATION
LET US HELP YOU!
  • What are the Known and Unknown Adjacencies Impacting the Sterility Testing Market
  • What will your New Revenue Sources be?
  • Who will be your Top Customer; what will make them switch?
  • Defend your Market Share or Win Competitors
  • Get a Scorecard for Target Partners
CUSTOMIZED WORKSHOP REQUEST
+1-888-600-6441
  • Call Us
  • +1-888-600-6441 (Corporate office hours)
  • +1-888-600-6441 (US/Can toll free)
  • +44-800-368-9399 (UK office hours)
CONNECT WITH US
ABOUT TRUST ONLINE
©2024 MarketsandMarkets Research Private Ltd. All rights reserved
DMCA.com Protection Status Website Feedback